Biovail news from FierceBiotech
NewsMelnyk outlines $100M blueprint for new developer
Fresh from losing an insurgent attack aimed at winning back control of Biovail, the Canadian entrepreneur says he plans to invest $50 million to $100 million of his own money to start a new R&D Read more...
Biovail focuses on CNS drugs
As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million Read more...
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
ALSO NOTED: U.S. hatches $265M regenerative medicine initiative; Merck KGaA budgets €1B for R&D;and much more...
> The U.S. government is creating a $265 million research initiative that will develop new stem cell technology to re-grow the skin, limbs and muscles of soldiers injured in Iraq and Afghanistan. Read more...
Biovail picks Wells as CEO
Canadian drugmaker Biovail has named a new chief to take the reigns from interim CEO Douglas Squires. William Wells has been appointed Biovail's new CEO, effective May 1, 2008. He's been on the Read more...
ALSO NOTED: R&D spending jumps; Bio-Imaging buys out Phoenix Data; Late-stage cancer drugs often successful; and much more...
> In a bid to broaden its clinical trial services offerings, Bio-Imaging has forged a deal to buy out Phoenix Data Systems for $24 million. Read more...
Melnyk slams Biovail board, calls for change
Biovail founder--and largest shareholder--Eugene Melnyk (photo) isn't happy with the company's management, and he's going to do something about it. Read more...
Biovail shares sink after FDA schedules review
Shares of Biovail took a dive this morning after the company announced that the FDA expects to take six months to review its application for BFV-033, a once-daily version of buproprion, which is sold Read more...
ALSO NOTED: University spins off drug delivery company; Millennium Phase II meets goal; Will the FDA get money to flex muscles?
> The University of Leuven has spun off Formac Pharmaceuticals, banking on new drug delivery technology to tackle poorly soluble molecules. Read more...
Biovail to drop analyst from lawsuit
Canada's Biovail has agreed to drop an analyst and his bank from the lengthy list of people and companies it sued last year, alleging a conspiracy to profit by cutting the biotech's stock price. The Read more...
| Press ReleasesPRESS RELEASE: Biovail Confirms FDA Class 2 Status For BVF-033 Submission Biovail Confirms FDA Class 2 Status For BVF-033 Submission TORONTO -- Nov. 20, 2007--Biovail Corporation today confirmed that the U.S. Food and Drug Administration (FDA) has classified the response Read more... PRESS RELEASE: Biovail Enters Into License and Development AgreementBiovail Enters Into License and Development Agreement TORONTO -- Biovail Corporation today announced that a subsidiary, Biovail Laboratories International SRL, has entered into a license and Read more... |
Get more Biovail coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends